During the study, the PI must maintain complete and accurate documentation for the study. The PI is responsible to ensure the accuracy, completeness, legibility, and timeliness of the protocol research nurse will collect data according to standardized research nursing procedures. Quality assurance requires maintaining complete records on each patient treated on the protocol, including primary documentation (e.g., laboratory reports, x-ray reports, scan reports, pathology reports, physician notes, etc.) that confirms the following: The patient met each eligibility criterion. Signed informed consent was obtained prior to treatment. (An on-study confirmation of eligibility form will be filled out before entering the study.) Documentation of specific dates and times of all treatments, doses administered, and the reason for any dose modification. Toxicity was assessed according to protocol (see section 5.4). Response was assessed according to protocol (x-ray, scan, lab reports, dated notes on measurements, and clinical assessment, as appropriate). NCI Drug Accountability Records were kept for each patient. Clinical data will be entered in a secure electronic database and hard copies will be stored in locked, secured areas. Completed eligibility checklists, patient information/registration forms, and blood sample flow sheets will also be stored. Copies of all records of adverse events will be kept in the research record. Complete records must be maintained on each patient, including the hospital chart with any supplementary information obtained from outside laboratories, radiology reports, or physician's records. These records will serve as the primary source material that forms the basis for the research record. All relevant data will also be entered in a computer database from which formal analyses will be done. The primary source documentation will include: on-study information, including patient eligibility data and patient history; flow sheets, records of adverse events, specialty forms for pathology, radiation, or surgery; and off-study summary sheets, including a final assessment by the treating physician. 41 Short Title: Enzalutamide Vaccine in mCRPC Version Date: 03/29/2022 5.2 DATA SHARING PLANS 5.2.1 Human Data Sharing Plan What data will be shared? I will share human data generated in this research for future research as follows: X Coded, linked data in an NIH-funded or approved public repository.